dabigatran etexilate + dronedarone

Dabigatran etexilate is an oral anticoagulant prodrug that is hydrolyzed to the active form, dabigatran, a direct and reversible thrombin inhibitor. It prevents the conversion of fibrinogen to fibrin, thereby impairing clot formation and reducing the risk of thromboembolic events such as stroke in patients with atrial fibrillation or after hip/knee replacement surgery. Dronedarone is an antiarrhythmic agent structurally related to amiodarone; it works by blocking multiple cardiac ion channels (calcium, potassium, sodium) and has antiadrenergic effects. Dronedarone slows nerve impulses in heart tissue to help maintain normal heart rhythm in patients with atrial fibrillation. When used together, there is a pharmacokinetic interaction due to dronedarone’s inhibition of P-glycoprotein (P-gp), which increases exposure to dabigatran[1][2][3][6]. Both drugs are approved for use in nonvalvular atrial fibrillation but require careful monitoring when co-administered due to increased bleeding risk.

Other names

dabigatrandabigatran etexilate mesylate